ReviewIranian journal of public health2024
Preeclampsia: Etiology, Pathophysiology, Risk Factors, Impact and Prevention: A Narrative Review.
Review in Iranian journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- SETD7-mediated epigenetic regulation of LncRNA XIST promotes trophoblast pyroptosis: a study in preeclampsia mouse and cell models.Biology direct · 2026Article
- Understanding Preeclampsia: Integrating Placental Dysfunction, Immune Dysregulation and microRNA-Mediated Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Second-Trimester Fibrinogen-to-Albumin Ratio and Platelet Activation Markers Compared with the HALP Score for Predicting Preeclampsia.Diagnostics (Basel, Switzerland) · 2026Article
- Effect of abnormal lipid profile on preeclampsia incidence and severity among Bangladesh women.Bioinformation · 2026Article
- Falling Third-Trimester Insulin Requirements in Diabetic Pregnancies and Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Role of agonistic autoantibodies to the angiotensin II type 1 receptor (AT1-AA) in pathogenesis of preeclampsia.Global medical genetics · 2025Review
- MicroRNAs in Preeclampsia: Bridging Diagnosis and Treatment.Journal of clinical medicine · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia (PE) caused 30%-40% of maternal and newborn deaths worldwide. Despite unclear exact cause, strategies exist to mitigate less severe PE effects. This review explores PE etiology, pathophysiology, risk factors, impact, and prevention. Methods: Searching Scopus, PubMed, ProQuest, Google Scholar, and Science Direct for "preeclampsia and pregnancy" and "prevention" yielded 2012-2022 articles. Results: Preeclampsia features abnormal placental changes, altered immunity response, trophoblast apoptosis, and reduced uterine perfusion. Risk factors include hypertension history, nulliparity, age over 40, BMI over 35 kg/m Conclusion: Findings emphasize enhancing health literacy and preeclampsia education in prenatal care to mitigate PE risk among women. Further research, novel therapies, and assessing prevention strategies with accessible educational materials and multidisciplinary approaches are warranted to enhance pregnant women's health literacy and decrease PE risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.